Introduction and objectives: Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are common causes of lower urinary tract symptoms (LUTS) in men. This multicenter study evaluated the efficacy of an entomological extract-based treatment (EEBT) as monotherapy and in combination with standard drugs. Materials and methods: A total of 6375 men with LUTS (IPSS ⩾ 10, Qmax 5–15 mL/s) were included; 1498 had BPH, 3060 had CP, and 1817 had both. Group I received EEBT monotherapy, while Group II underwent combination therapy with α1-adrenergic blockers, NSAIDs, antibiotics, and other agents. Outcomes were assessed after 30 days using NIH-CPSI, IPSS, IIEF-5, QoL, Qmax, prostate volume, and residual urine. Results: Both regimens significantly improved LUTS. In BPH patients, monotherapy reduced prostate and residual urine volumes and improved IIEF-5, whereas combination therapy provided greater symptom relief. In CP patients, both regimens improved NIH-CPSI, IPSS, and urinary flow, with monotherapy showing superior QoL benefits. In men with BPH + CP, monotherapy favored erectile function, while combination therapy improved IPSS. All subgroups demonstrated significant gains in Qmax. Treatment was well tolerated; only mild Clavien–Dindo grade I and II adverse events were reported, with no serious complications. Conclusion: EEBT is effective as both monotherapy and in combination therapy for LUTS associated with BPH and CP, supporting its role in personalized treatment strategies.
Kasyan et al. (Fri,) studied this question.